41.49 USD
↘ 0.03 (0.07%)AT CLOSE (03:59 PM EDT)
Enliven Therapeutics, Inc. Common Stock
ELVNNASDAQ • USD
41.57
↗ 0.08 (0.19%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
41.57
↗ 0.08 (0.19%)
Market: CLOSED
ELVN is currently priced at $41.51. The technical outlook is "Sell" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, ELVN trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Oct 26, 2026.
Open?$41.58
High?$42.18
Low?$40.90
Prev. Close?$41.52
Volume?3.8M
Avg. Volume?1.6M
VWAP?$41.27
Rel. Volume?2.32x
Bid / Ask
Bid?$40.60 × 300
Ask?$42.14 × 300
Spread?$1.54
Midpoint?$41.37
Valuation & Ratios
Market Cap?3.0B
Shares Out?73.3M
Float?56.9M
Float %?77.7%
P/E Ratio?N/A
P/B Ratio?3.40
EPS?-$1.45
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Employees
67
Market Cap
3.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2023-02-24
Address
205 PARK ROAD
BURLINGAME, CA 94010
Phone: 650-547-5814
BURLINGAME, CA 94010
Phone: 650-547-5814
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?30
Piotroski F-Score?0/9Weak
Altman Z-Score?121.11Safe
Confidence?52%Low
Short InterestHigh
Short % of Float?16.39%High
Short Interest?9.3M
Days to Cover?7.5
Free Float56.9M
Avg Daily Volume1.3M
Settlement Date2026-10-15
Financial Health
Current Ratio?64.07Strong
Quick Ratio?64.07Strong
Cash Ratio?9.57Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?3.40FAIR▾
Peers100
S&P50
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-23.4CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-11.8%WEAK▾
S&P9
ROA?-11.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-67037000
Enterprise Value?$2.9B
Fundamentals ratios updated end of day